chartexchange

FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track

GlobeNewswire Inc. | Nov 11, 2026 8:37 AM EST

NeOnc (NASDAQ: NTHI) secured an FDA Type B End-of-Phase meeting, early January 2027, to discuss a potential accelerated approval pathway for NEO100

Read original article